CLINICAL_TRIALS ClinicalTrials.gov record update

MCLENA-2: A Phase II Clinical Trial for the Assessment of Biomarker Trajectory in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease Treated With Lenalidomide (Amendment to IND # 142121)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT06177028
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:47.138719+00:00
Published At: 2025-05-18T00:00:00+00:00
Record Updated At: 2025-05-18
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Cognitive Impairment, Mild", "Cognitive Dysfunction", "Amyloid Plaque", "Neurodegenerative Disease, Hereditary", "Inflammation, Brain"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-05-18"
protocolSection.identificationModule.nctId: "NCT06177028"
protocolSection.identificationModule.officialTitle: "MCLENA-2: A Phase II Clinical Trial for the Assessment of Biomarker Trajectory in Patients With Mild Cognitive Impairment Due to Alzheimer\u0027s Disease Treated With Lenalidomide (Amendment to IND # 142121)"
protocolSection.statusModule.overallStatus: "NOT_YET_RECRUITING"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.